Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report
- PMID: 35720101
- PMCID: PMC9201402
- DOI: 10.3389/fneur.2022.908282
Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report
Abstract
Guillain-Barré syndrome(GBS) is an autoimmune-mediated peripheral neuropathy. Immune checkpoint inhibitors (ICIs) are the standard treatment for cancer and may lead to immune-related adverse events (irAEs) such as GBS. Corticosteroids, plasma exchange (PE), and intravenous immunoglobulin (IVIG) are currently accepted treatments for ICI-induced GBS. However, there are still adverse reactions, and the effect of relieving symptoms is not as good as expected. Safe and effective complementary replacement therapy to alleviate GBS symptoms and ameliorate the quality of life is urgently required. In this case, a 63-year-old man received ICI therapy and antitumor chemotherapy for lung malignancy. After two courses of treatment, the patient gradually developed limb weakness, numbness, and pain at the ends of the limbs, with cerebrospinal fluid (CSF) albuminocytological dissociation, and electromyography (EMG) suggested demyelinating changes and was diagnosed as GBS. Although the patient received high doses of intravenous gamma globulin and limb weakness symptoms were alleviated, there was still significant numbness and pain in the extremities. After four times of acupuncture treatments, the patient complained that the symptoms of limb numbness and fatigue were significantly alleviated without any discomfort. This case report may provide a new alternative and complementary therapy for immune checkpoint inhibitor-induced GBS, but more definitive and robust evidence is needed to support its efficacy.
Keywords: Guillain–Barré syndrome; acupuncture; case report; immune checkpoint inhibitors; immune-related adverse events; limb weakness; numbness.
Copyright © 2022 Li, Xu, Liu, Cao, He and Liao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.Front Immunol. 2023 May 8;14:1132692. doi: 10.3389/fimmu.2023.1132692. eCollection 2023. Front Immunol. 2023. PMID: 37223099 Free PMC article.
-
Case report: Resolution of Guillain-Barré syndrome in a patient with dual primary tumors after treatment with rituximab.Front Neurol. 2024 Feb 21;15:1348304. doi: 10.3389/fneur.2024.1348304. eCollection 2024. Front Neurol. 2024. PMID: 38450071 Free PMC article.
-
Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review.Cureus. 2024 Jun 1;16(6):e61489. doi: 10.7759/cureus.61489. eCollection 2024 Jun. Cureus. 2024. PMID: 38952584 Free PMC article.
-
Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.J Immunother. 2021 Sep 1;44(7):276-282. doi: 10.1097/CJI.0000000000000364. J Immunother. 2021. PMID: 33758147 Review.
-
Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.Biomed Res Int. 2021 Aug 19;2021:9800488. doi: 10.1155/2021/9800488. eCollection 2021. Biomed Res Int. 2021. PMID: 34458371 Free PMC article.
Cited by
-
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.Front Immunol. 2023 Mar 6;14:1094414. doi: 10.3389/fimmu.2023.1094414. eCollection 2023. Front Immunol. 2023. PMID: 36949956 Free PMC article. Review.
-
Fire acupuncture for anti-LGI1 antibody autoimmune encephalitis: a case report.Front Neurosci. 2023 Jul 19;17:1203915. doi: 10.3389/fnins.2023.1203915. eCollection 2023. Front Neurosci. 2023. PMID: 37539383 Free PMC article.
-
Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.Chin Med. 2023 May 20;18(1):59. doi: 10.1186/s13020-023-00751-7. Chin Med. 2023. PMID: 37210537 Free PMC article. Review.
-
Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors.Front Immunol. 2024 Nov 26;15:1429483. doi: 10.3389/fimmu.2024.1429483. eCollection 2024. Front Immunol. 2024. PMID: 39660124 Free PMC article. Review.
-
Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.Front Immunol. 2023 May 8;14:1132692. doi: 10.3389/fimmu.2023.1132692. eCollection 2023. Front Immunol. 2023. PMID: 37223099 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources